- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05344482
Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis
A Retrospective Multicenter Study for the Assessment of Effectiveness of Secukinumab as Assessed by Psoriasis Area and Severity Index With Subcutaneous Administration in Adult Patients With Moderate to Severe Plaque Psoriasis in Turkish Population
Study Overview
Detailed Description
The study was a retrospective, multicenter, cohort study which was based on data collection at week 4,16 and 52 of secukinumab treatment of moderate to severe plaque psoriasis.
The observational design of the study allowed data collection about secukinumab treatment patterns and clinical and demographic characteristics of plaque psoriasis patients treated with secukinumab for 52 weeks in Turkey. The adults included in the study were treated with secukinumab for 52 weeks. The adults with no available data of PASI scores at specific time points (4, 16 and 52 weeks) and no definite description of treatment cessation were excluded. The study population consisted of adults treated with secukinumab for 52 weeks and adults dropped out before 52 weeks with available data of PASI scores at 4, 16 and 52 weeks and definite description of treatment cessation.
Retrospective data collection from secondary sources (hospital medical records) allowed time and cost saving since description of patients' characteristics, analyses of outcomes of interest and their determinants could be made in a short period of time.
The study consisted of the following periods:
- The index date was the date of initiation of secukinumab
- The study (index) period was between 18 May 2018 to 31 May 2020
- The follow-up (post-index) period was 4,16 and 52 weeks post-index
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New Jersey
-
East Hanover, New Jersey, United States, 07936-1080
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- A diagnosis of psoriasis
- Age ≥ 18 years at registry baseline.
- Patients with a firm diagnosis of chronic plaque psoriasis for at least 6 months before enrollment
- Secukinumab treatment should be initiated 52 weeks before data collection date
- Moderate to severe plaque psoriasis with PASI score of ≥10 before initiating secukinumab.
Exclusion Criteria:
- Patients diagnosed with others types of psoriasis (pustular psoriasis, erythrodermic psoriasis etc) are excluded.
- Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Overall cohort: Secukinumab
Included all the patients treated with secukinumab
|
Included all the patients treated with secukinumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients having absolute Psoriasis Area and Severity Index PASI≤3 at week 52
Time Frame: at week 52
|
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease).
Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI.
For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum).
Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
Assessment of the effectiveness of secukinumab in subjects with moderate to severe plaque psoriasis was performed based on the percentage of patients who had absolute PASI ≤3 at week 52 in Turkey.
|
at week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients experiencing a 75% reduction in PASI (PASI75) from baseline
Time Frame: at week 4
|
Speed of response to secukinumab according to previous biologic use was demonstrated.
|
at week 4
|
Percentage of patients experiencing a 75% reduction in PASI (PASI90) from baseline
Time Frame: at week 16
|
Speed of response to secukinumab according to previous biologic use was demonstrated.
|
at week 16
|
Percentage of PASI 90 responders at week 52 out of PASI 90 responders at week 16
Time Frame: at week 16 and week 52
|
Sustainability rate between week 16 and week 52 which is defined as PASI 90 scores at both milestones was assessed.
|
at week 16 and week 52
|
Percentage of patients experiencing a 100% reduction in PASI (PASI100) from baseline
Time Frame: at week 52
|
PASI 100 responders rate at week 52 was assessed.
|
at week 52
|
Percentage of PASI 90 responders among biologic naive patients vs. biologic experienced patients
Time Frame: at week 52
|
Responders rates for biologic naive vs. non-naive patients in terms of PASI 90 at week 52 was evaluated.
|
at week 52
|
Percentage of PASI 90 responder rates at week 52 among smokers vs. non-smokers
Time Frame: at week 52
|
Effect of secukinumab treatment response for psoriasis patients (between smokers vs. non-smokers) at week 52 was assessed
|
at week 52
|
Percentage of PASI 75 responder rates among very severe (PASI>20) patients prior the treatment
Time Frame: at week 52
|
Effectiveness of secukinumab treatment for very severe ( PASI>20 ) psoriatic patients at week 52 was demonstrated.
|
at week 52
|
Nail psoriasis: percentage of patients experiencing nail psoriasis, number of finger nails involved
Time Frame: at week 52
|
Effectiveness of secukinumab in psoriatic manifestations was demonstrated.
|
at week 52
|
Palmoplantar psoriasis: percentage of patients experiencing palmoplantar psoriasis
Time Frame: at week 52
|
Effectiveness of secukinumab in psoriatic manifestations was demonstrated.
|
at week 52
|
Scalp psoriasis: percentage of patients experiencing scalp psoriasis
Time Frame: at week 52
|
Effectiveness of secukinumab in psoriatic manifestations was demonstrated.
|
at week 52
|
Psoriatic arthritis: percentage of patients experiencing psoriatic arthritis
Time Frame: at week 52
|
Effectiveness of secukinumab in psoriatic manifestations was demonstrated.
|
at week 52
|
Percentage of patients who discontinued secukinumab at 52 weeks period
Time Frame: at week 52
|
Drug survival as measured by percentage of patients who were persistent secukinumab users, or percentage of patients who discontinued secukinumab at 52 weeks period was reported to describe secukinumab treatment utilization patterns.
|
at week 52
|
Time to discontinuation
Time Frame: at week 52
|
Time to discontinuation defined as time from treatment initiation to treatment stop.
For patients who stopped secukinumab but re initiated treatment within 90 days after stop date without any other systemic treatment in between will be considered as continued/persistent users.
|
at week 52
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAIN457ATR02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plaque Psoriasis
-
UCB Biopharma SRLRecruitingModerate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis | Mixed Guttate/Plaque PsoriasisUnited States, Canada, Puerto Rico
-
Idera Pharmaceuticals, Inc.CompletedModerate to Severe Plaque Psoriasis | Actively Extending Plaque PsoriasisUnited States
-
Fresenius Kabi SwissBioSim GmbHMerck KGaA, Darmstadt, GermanyCompletedPsoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type PsoriasisUnited States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
-
UCB Biopharma SRLCompletedModerate to Severe Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey, United Kingdom
-
Biocon Biologics Inc.MEDA Pharma GmbH & Co. KG; Mylan Inc.; IQVIA Pvt. LtdCompletedHulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and ImmunogenicityModerate Chronic Plaque Psoriasis | Severe Chronic Plaque PsoriasisBulgaria, Czechia, Estonia, Poland
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Canada
-
UCB Biopharma SRLActive, not recruitingModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisChina
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
Clinical Trials on Secukinumab
-
Novartis PharmaceuticalsRecruiting
-
Technical University of MunichNovartisCompletedPyoderma GangrenosumGermany
-
Novartis PharmaceuticalsCompletedPlaque PsoriasisThailand
-
University of Erlangen-Nürnberg Medical SchoolActive, not recruiting
-
Novartis PharmaceuticalsCompletedPsoriatic Arthritis | Axial SpondyloarthritisSpain
-
Novartis PharmaceuticalsCompletedPsoriasisUnited States
-
Saakshi KhattriCompleted
-
Novartis PharmaceuticalsTerminatedLupus NephritisChina, Croatia, Czechia, Russian Federation, Turkey, Australia, Spain, Thailand, Argentina, United States, Denmark, Greece, Romania, Germany, Korea, Republic of, India, Brazil, Japan, Peru, Portugal, Italy, Taiwan, Vietnam, Norway, Colo... and more
-
Novartis PharmaceuticalsCompleted